Esperion Therapeutics, Inc.

NasdaqGM:ESPR 주식 리포트

시가총액: US$803.1m

Esperion Therapeutics 경영진

경영진 기준 점검 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Sheldon Koenig

최고경영자

US$3.5m

총 보수

CEO 급여 비율21.80%
CEO 재임 기간5yrs
CEO 지분 보유율0.2%
경영진 평균 재임 기간3.8yrs
이사회 평균 재임 기간3.8yrs

최근 경영진 업데이트

Recent updates

ESPR: Vision 2040 And Corstasis Deal Will Balance Downgrade Concerns

Narrative Update on Esperion Therapeutics The updated analyst price target for Esperion Therapeutics has moved closer to recent Street views, rising from a fair value estimate of $1.78 to $3.16. Analysts are weighing recent downgrades against research that cites consistent Q4 results, progress on the Vision 2040 plan, and pipeline expansion, including the Corstasis Therapeutics acquisition and ESP-2001 advancement.

ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk

Analysts recently lifted their price target on Esperion Therapeutics to $5 from $4, citing Q4 results that aligned with earlier guidance and continued progress on the Vision 2040 plan, including the Corstasis Therapeutics acquisition and advancement of ESP-2001. Analyst Commentary Recent commentary around Esperion focuses on how the updated US$5 price target lines up with the company’s execution on its Vision 2040 plan.

ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks

Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.

ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside

Narrative Update Overview Analysts have lifted their price target on Esperion Therapeutics to $5, up from $4, citing continued execution on Vision 2040, the Corstasis Therapeutics acquisition, and progress with ESP-2001 as key drivers behind the updated valuation inputs. These inputs include a higher fair value estimate and adjusted discount rate and P/E assumptions.

ESPR: Patent Litigation Outcomes Will Likely Expose Weak Profitability Execution Risks

Analysts have revised their price target for Esperion Therapeutics to align with updated assumptions that keep fair value steady at about $1.78 per share. This reflects higher modeled revenue growth, balanced by lower projected profit margins and a slightly reduced future P/E multiple.

ESPR: Overweight Rating Will Likely Conceal Risk Around Patent And Profitability Execution

Analysts have adjusted their price target on Esperion Therapeutics to $9, reflecting updated assumptions for revenue growth, profit margin, and forward P/E. This change is supported by recent Street research highlighting the new coverage and target level.

ESPR: Overweight Rating Will Likely Mask Execution Risk Around Acquisition Strategy

Analysts have raised their price target for Esperion Therapeutics to about US$1.78 from roughly US$1.72, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E. These changes reflect the recent US$9 initiation from Piper Sandler as part of a broader reassessment of the stock's earnings power and risk profile.

ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment

Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler. Analyst Commentary Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.

ESPR: Overweight Rating Will Likely Obscure Persistent Execution And Profitability Risks

Narrative Update on Esperion Therapeutics Analysts have lifted their price target on Esperion Therapeutics to US$9, citing updated assumptions for revenue growth, profitability, and future P/E that reflect a more constructive view of the company’s earnings potential. Analyst Commentary Recent coverage highlights a more constructive stance on Esperion Therapeutics, with a US$9 price target used as a reference point for what the business might be worth if current assumptions on revenue and earnings play out as expected.

ESPR: Rising Street Optimism Will Likely Mask Lingering Execution Risks

Analysts have raised their price target on Esperion Therapeutics to $9.00 from $7.00, reflecting increased confidence in the stock's valuation despite moderating long term growth and margin assumptions. Analyst Commentary Recent Street research has reflected a cautiously optimistic stance toward Esperion Therapeutics, with new coverage and revised price targets coalescing around the $9 level.

ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares

Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.

ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares

Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.

ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance

Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now

Sep 09

Rising Digital Adoption And Global Partnerships Will Shape Future Markets

Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
User avatar

US FDA Approvals And Global Expansion Will Shape Future Markets

International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.

Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug

Feb 22

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Dec 08

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13

Esperion Therapeutics: Strategically Positioned To Grow

Aug 16

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

CEO 보수 분석

Sheldon Koenig의 보수는 Esperion Therapeutics의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025US$4mUS$771k

-US$23m

Sep 30 2025n/an/a

-US$106m

Jun 30 2025n/an/a

-US$104m

Mar 31 2025n/an/a

-US$153m

Dec 31 2024US$3mUS$746k

-US$52m

Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$98m

Mar 31 2024n/an/a

-US$87m

Dec 31 2023US$3mUS$721k

-US$209m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$222m

Mar 31 2023n/an/a

-US$239m

Dec 31 2022US$4mUS$683k

-US$234m

Sep 30 2022n/an/a

-US$243m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$8mUS$566k

-US$269m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$325m

Mar 31 2021n/an/a

-US$156m

Dec 31 2020US$508kUS$23k

-US$144m

보상 대 시장: Sheldon의 총 보수(USD3.54M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.69M) 수준입니다.

보상과 수익: Sheldon의 보상은 회사가 적자임에도 증가했습니다.

CEO

Sheldon Koenig (59 yo)

5yrs
재임 기간
US$3,535,512
보수

Mr. Sheldon L. Koenig, M.B.A. is Business Advisor Sarcomatrix Therapeutics, Corp. Mr. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and h...

리더십 팀

이름직위재임 기간보수지분
Sheldon Koenig
President5yrsUS$3.54m0.22%
$ 1.8m
Benjamin Halladay
Chief Financial Officer3.5yrsUS$1.35m0.075%
$ 599.4k
John Harlow
Chief Commercial Officerless than a yearUS$3.29m0.16%
$ 1.3m
Glenn Brame
Chief Technical Operations Officer3.3yrs데이터 없음데이터 없음
Benjamin Looker
Chief Legal & Corporate Affairs Officer4.3yrsUS$1.13m0.060%
$ 484.8k
Tiffany Aldrich
Associate Director of Corporate Communicationsno data데이터 없음데이터 없음
Betty Swartz
Chief Business Officer4.2yrs데이터 없음데이터 없음
LeAnne Bloedon
VP & Head of Developmentno data데이터 없음데이터 없음
Stephen Pinkosky
Vice President of Drug Discovery of Early Pre-Clinical Developmentno data데이터 없음데이터 없음
3.8yrs
평균 재임 기간
49yo
평균 나이

경험이 풍부한 관리: ESPR의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.8 년).

이사회 구성원

이름직위재임 기간보수지분
Sheldon Koenig
President5yrsUS$3.54m0.22%
$ 1.8m
Robert Hoffman
Independent Director1.1yrsUS$86.38k0.0021%
$ 16.5k
Jay Shepard
Independent Director8yrsUS$127.71k0.033%
$ 264.0k
Stephen Rocamboli
Independent Director4.1yrsUS$124.70k0.027%
$ 216.1k
J. Carroll
Independent Chairperson3.9yrsUS$152.20k0.038%
$ 304.7k
Peter Libby
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음
Seth H. Fischer
Independent Director4.6yrsUS$132.71k0.024%
$ 190.8k
Tracy Woody
Independent Director7yrsUS$129.21k0.013%
$ 104.7k
R. Mason
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음
David Cohen
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음
Karin Bornfeldt
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음
Pradeep Natarajan
Member of Scientific Advisory Board3.8yrs데이터 없음데이터 없음
3.8yrs
평균 재임 기간
63yo
평균 나이

경험이 풍부한 이사회: ESPR의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.8 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/05 22:34
종가2026/05/05 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Esperion Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Jason ZemanskyBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC